Repositioning Candidate Details

Candidate ID: R0749
Source ID: DB05235
Source Type: investigational
Compound Type: small molecule
Compound Name: NRP409
Synonyms: --
Molecular Formula: --
SMILES: --
DrugBank Description: NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
CAS Number: --
Molecular Weight:
DrugBank Indication: For use in treatment of hypothyroidism.
DrugBank Pharmacology: The company is hoping that NRP409 will mark a significant improvement in thyroid HRT by reducing the variability of the more active hormone's availability, while reducing the safety risk associated with other T3 based therapies.
DrugBank MoA: NRP409 is presumed to work like the endogenous thyroid hormone thyroxine (T<sub>4</sub>, a tetra-iodinated tyrosine derivative). In the liver and kidney, T<sub>4</sub> is converted to T<sub>3</sub>, the active metabolite. In order to increase solubility, the thyroid hormones attach to thyroid hormone binding proteins, thyroxin-binding globulin, and thyroxin-binding prealbumin (transthyretin). Transport and binding to thyroid hormone receptors in the cytoplasm and nucleus then takes place. Thus by acting as a replacement for natural thyroxine, symptoms of thyroxine deficiency are relieved.
Targets: Ketimine reductase mu-crystallin; Thyroid hormone receptor alpha
Inclusion Criteria: Indication associated